A systems biology road map for the discovery of drugs targeting cancer cell metabolism

Current Pharmaceutical Design

Volumn 20, Issue 15, 2014, Pages 2648-2666

  Alberghina, Lilia ^a,b   Gaglio, Daniela ^a,c   Moresco, Rosa Maria ^a,b,c   Gilardi, Maria Carla ^a,b,c   Messa, Cristina ^a,b,c   Vanoni, Marco ^a,b  

^a SYSBIO Centre for Systems Biology   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

Author keywords

Glutamine; Metabolic rewiring; Model; Warburg effect

Indexed keywords

ANTINEOPLASTIC AGENT; MEMBRANE RECEPTOR; GLUCOSE; GLUTAMINE;

ARTICLE; CANCER CELL; CANCER CONTROL; CANCER GROWTH; CELL DIFFERENTIATION; CELL GROWTH; CELL METABOLISM; CELL SURVIVAL; DRUG DEGRADATION; FATTY ACID SYNTHESIS; GENE MUTATION; GENOMIC INSTABILITY; GLYCOLYSIS; HUMAN; INTRACELLULAR SIGNALING; MATHEMATICAL MODEL; PENTOSE PHOSPHATE CYCLE; PHENOTYPE; PRIORITY JOURNAL; SENESCENCE; SYSTEMS BIOLOGY; TUMOR RESISTANCE; DRUG DEVELOPMENT; DRUG RESISTANCE; METABOLISM; NEOPLASMS; PROCEDURES; SIGNAL TRANSDUCTION;

DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; GENOMIC INSTABILITY; GLUCOSE; GLUTAMINE; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

EID: 84903690620     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990490     Document Type: Article

References (240)

1. Boyle P, Levin B. In: In: World Cancer Report, World Health Organization IAfRiC, Lyon, France: IARC Press 2008., eds.
2. Rous P. A Sarcoma of the Fowl Transmissible by an Agent Separable from the Tumor Cells. J Exp Med 1911; 13(4): 397-411.
3. Weinberg RA. The Biology of Cancer. New York: Garland Sci 2007.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-74.
6. Alberghina L, Gaglio D, Gelfi C, et al. Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling. Frontiers Physiol 2012; 3: 362.
7. Alberghina L, Westerhoff H. SystemsBiology: Definitions and Perspectives.: Heidelberg: Springer 2005.
8. Bhalla US, Iyengar R. Emergent properties of networks of biological signaling pathways. Science (New York, NY 1999; 283(5400): 381-7.
9. Chiaradonna F, Moresco RM, Airoldi C, et al. From cancer metabolism to new biomarkers and drug targets. Biotechnol Adv 2012; 30(1): 30-51.
10. Chiaradonna F, Sacco E, Manzoni R, Giorgio M, Vanoni M, Alberghina L. Ras-dependent carbon metabolism and transformation in mouse fibroblasts. Oncogene 2006; 25(39): 5391-404.
11. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009; 124(3): 511-5.
12. Graham NA, Tahmasian M, Kohli B, et al. Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Mole Systems Biol 2012; 8: 589.
13. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11(3): 220-8.
14. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G: C-->T: A mutations in colorectal tumors. Nature Genet 2002; 30(2): 227-32.
15. Kennedy RD, D'Andrea AD. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 2006; 24(23): 3799-808.
16. Ripperger T, Gadzicki D, Meindl A, Schlegelberger B. Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet 2009; 17(6): 722-31.
17. Bachrati CZ, Hickson ID. RecQ helicases: suppressors of tumorigenesis and premature aging. Biochem J 2003; 374(Pt 3): 577-606.
18. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science (New York, NY 2006; 314(5797): 268-74.
19. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science (New York, NY 2007; 318(5853): 1108-13.
20. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (New York, NY 2008; 321(5897): 1801-6.
21. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science (New York, NY 2008; 321(5897): 1807-12.
22. McLendon R, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455(7216): 1061-8.
23. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Develop 2010; 24(22): 2463-79.
24. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426(6963): 194-8.
25. Herbig U, Jobling WA, Chen BP, Chen DJ, Sedivy JM. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Molecular Cell 2004; 14(4): 501-13.
26. von Zglinicki T, Martin-Ruiz CM. Telomeres as biomarkers for ageing and age-related diseases. Curr Molecular Med 2005; 5(2): 197-203.
27. Banito A, Rashid ST, Acosta JC, et al. Senescence impairs successful reprogramming to pluripotent stem cells. Genes & development 2009; 23(18): 2134-9.
28. Hong H, Takahashi K, Ichisaka T, et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009; 460(7259): 1132-5.
29. Kawamura T, Suzuki J, Wang YV, et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009; 460(7259): 1140-4.
30. Li H, Collado M, Villasante A, et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009; 460(7259): 1136-9.
31. Marion RM, Strati K, Li H, et al. Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell stem cell 2009; 4(2): 141-54.
32. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Development 2009; 23(5): 537-48.
33. Bianco R, Melisi D, Ciardiello F, Tortora G. Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer 2006; 42(3): 290-4.
34. Bertram JS. The molecular biology of cancer. Mol Aspects Med 2000; 21(6): 167-223.
35. Paul MK, Mukhopadhyay AK. Tyrosine kinase-Role and significance in Cancer. Int J medical sciences 2004; 1(2): 101-15.
36. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 1990; 50(21): 7077-80.
37. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19(56): 6550-65.
38. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocrine-related Cancer 2001; 8(2): 83-96.
39. Nickerson NK, Mohammad KS, Gilmore JL, et al. Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad. PloS one 2012; 7(1): e30255.
40. Nazarenko I, Hede SM, He X, et al. PDGF and PDGF receptors in glioma. Upsala J Med Sci 2012; 117(2): 99-112.
41. Stella GM, Benvenuti S, Comoglio PM. Targeting the MET oncogene in cancer and metastases. Exp Opinion Investigational Drugs 2010; 19(11): 1381-94.
42. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11(12): 834-48.
43. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15(7): 2207-14.
44. Zha J, Lackner MR. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 2010; 16(9): 2512-7.
45. Tomankova H, Myslivecek J. Mechanisms of G protein-coupled receptors regulation. Neuro Endocrinol Lett 2011; 32(5): 607-15.
46. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev 2007; 7(2): 79-94.
47. Almendro V, Garcia-Recio S, Gascon P. Tyrosine kinase receptor transactivation associated to G protein-coupled receptors. Curr drug targets 2010; 11(9): 1169-80.
48. Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition.: New York: Garland Science; 2002.
49. Lanave C, Colangelo AM, Saccone C, Alberghina L. Molecular evolution of the neurotrophin family members and their Trk receptors. Gene 2007; 394(1-2): 1-12.
50. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors (Chur, Switzerland) 2006; 24(1): 21-44.
51. Eckert LB, Repasky GA, Ulku AS, et al. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res 2004; 64(13): 4585-92.
52. Moritz A, Li Y, Guo A, et al. Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci Signaling 2010; 3(136): ra64.
53. Sun Q, Chen X, Ma J, et al. Mammalian target of rapamycin upregulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 2011; 108(10): 4129-34.
54. Tanaka K, Babic I, Nathanson D, et al. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov 2011; 1(6): 524-38.
55. Zhang HH, Huang J, Duvel K, et al. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PloS one 2009; 4(7): e6189.
56. Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opinion Cell Biol 2010; 22(2): 169-76.
57. Yecies JL, Manning BD. mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med (Berlin, Germany) 2011; 89(3): 221-8.
58. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012; 72(10): 2457-67.
59. Scheffzek K, Ahmadian MR, Kabsch W, et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science (New York, NY 1997; 277(5324): 333-8.
60. Palmioli A, Sacco E, Airoldi C, et al. Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D). Biochem Biophysical Res Communications 2009; 386(4): 593-7.
61. Zippel R, Demaddalena C, Porro G, Modena D, Sturani E, Vanoni M. Increased p21ras-specific Guanine-nucleotide exchange causes tumor-formation in nude-mice. Int J Oncol 1994; 4(1): 175-9.
62. Roberts AE, Araki T, Swanson KD, et al. Germline gain-offunction mutations in SOS1 cause Noonan syndrome. Nat Genetics 2007; 39(1): 70-4.
63. Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Human Mutation 2008; 29(8): 992-1006.
64. Bentires-Alj M, Kontaridis MI, Neel BG. Stops along the RAS pathway in human genetic disease. Nature Med 2006; 12(3): 283-5.
65. Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr Topics Microbiol Immunol 2010; 347: 21-41.
66. Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opinion Genetics Development 2008; 18(1): 73-9.
67. Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Investigat 2011; 121(10): 3797-803.
68. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. The oncologist 2002; 7 Suppl 4: 2-8.
69. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science (New York, NY 2006; 312(5777): 1175-8.
70. Glennie MJ, Honeychurch J, French RR, Tutt AL. The application of monoclonal antibodies in the treatment of lymphoma. Methods Mol Med 2000; 40: 85-97.
71. Glennie MJ, Johnson PW. Clinical trials of antibody therapy. Immunol Today 2000; 21(8): 403-10.
72. Waldmann TA. Immunotherapy: past, present and future. Nature Med 2003; 9(3): 269-77.
73. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science (New York, NY 2002; 298(5600): 1912-34.
74. Sebolt-Leopold JS. Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin Cancer Res 2008; 14(12): 3651-6.
75. Boston SR, Deshmukh R, Strome S, Priyakumar UD, MacKerell AD, Jr., Shapiro P. Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9. BMC Cancer 2011; 11: 7.
76. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5(10): 835-44.
77. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417(6892): 949-54.
78. Wong KK. Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. Recent patents on anti-cancer drug discovery 2009; 4(1): 28-35.
79. Trujillo JI. MEK inhibitors: a patent review 2008-2010. Expert Opinion Therapeutic Patents 2011; 21(7): 1045-69.
80. Sacco E, Spinelli M, Vanoni M. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007-present). Exp Opinion Therapeut Patents 2012; 22(11): 1263-87.
81. Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem 2011; 3(14): 1787-808.
82. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26(1): 127-32.
83. Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007; 99(8): 628-38.
84. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signaling 2010; 3(149): ra84.
85. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486(7404): 532-6.
86. Diaz LA, Jr., Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486(7404): 537-40.
87. Troiani T, Vecchione L, Martinelli E, et al. Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. Br J Cancer 2012; 106(10): 1648-59.
88. Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat Rev Drug Discov 2011; 10(11): 811-2.
89. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468(7326): 973-7.
90. Straussman R, Morikawa T, Shee K, et al. Tumour microenvironment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487(7408): 500-4.
91. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483(7387): 100-3.
92. Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487(7408): 505-9.
93. Conley SJ, Gheordunescu E, Kakarala P, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 2012; 109(8): 2784-9.
94. Van der Veldt AA, Lubberink M, Bahce I, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012; 21(1): 82-91.
95. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458(7239): 719-24.
96. Miller DG. On the nature of susceptibility to cancer. The presidential address. Cancer 1980; 46(6): 1307-18.
97. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18(1): 11-22.
98. Gray J, Druker B. Genomics: the breast cancer landscape. Nature. Jun 21; 486(7403): 328-9.
99. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483(7391): 603-7.
100. Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483(7391): 570-5.
101. Dar AC, Das TK, Shokat KM, Cagan RL. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 2012; 486(7401): 80-4.
102. Gohil VM, Sheth SA, Nilsson R, et al. Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis. Nat Biotechnol 2010; 28(3): 249-55.
103. Platzer A, Perco P, Lukas A, Mayer B. Characterization of proteininteraction networks in tumors. BMC Bioinformat 2007; 8: 224.
104. Li BQ, Huang T, Liu L, Cai YD, Chou KC. Identification of colorectal cancer related genes with mRMR and shortest path in protein-protein interaction network. PloS one 2012; 7(4): e33393.
105. Wu C, Zhu J, Zhang X. Integrating gene expression and proteinprotein interaction network to prioritize cancer-associated genes. BMC Bioinformat 2012; 13: 182.
106. Wu G, Feng X, Stein L. A human functional protein interaction network and its application to cancer data analysis. Genome Biol 2010; 11(5): R53.
107. Hase T, Tanaka H, Suzuki Y, Nakagawa S, Kitano H. Structure of protein interaction networks and their implications on drug design. PLoS computational Biol 2009; 5(10): e1000550.
108. Shiraishi T, Matsuyama S, Kitano H. Large-scale analysis of network bistability for human cancers. PLoS computational Biol 2010; 6(7): e1000851.
109. Alberghina L, Hofer T, Vanoni M. Molecular networks and system-level properties. J Biotechnol 2009; 144(3): 224-33.
110. Schmidt BJ, Papin JA, Musante CJ. Mechanistic systems modeling to guide drug discovery and development. Drug discovery today 2012 Sep 19.
111. Oberhardt MA, Palsson BO, Papin JA. Applications of genomescale metabolic reconstructions. Molecular systems biology 2009; 5: 320.
112. Zamboni N, Sauer U. Novel biological insights through metabolomics and 13C-flux analysis. Curr Opinion Microbiol 2009; 12(5): 553-8.
113. Duarte NC, Becker SA, Jamshidi N, et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Nat Acad Sci USA 2007; 104(6): 1777-82.
114. Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, Shlomi T. Predicting selective drug targets in cancer through metabolic networks. Molecular Systems Biol 2011; 7: 501.
115. Jamshidi N, Palsson BO. Mass action stoichiometric simulation models: incorporating kinetics and regulation into stoichiometric models. Biophysical J 2010; 98(2): 175-85.
116. Shlomi T, Benyamini T, Gottlieb E, Sharan R, Ruppin E. Genomescale metabolic modeling elucidates the role of proliferative adaptation in causing the Warburg effect. PLoS computational Biol 2011; 7(3): e1002018.
117. Simeonidis E, Murabito E, Smallbone K, Westerhoff HV. Why does yeast ferment? A flux balance analysis study. Biochemical Soc Transactions 2010; 38(5): 1225-9.
118. Kitano H. Grand challenges in systems physiology. Frontiers in physiology 2010; 1: 3.
119. Karr JR, Sanghvi JC, Macklin DN, et al. A whole-cell computational model predicts phenotype from genotype. Cell 2012; 150(2): 389-401.
120. Warburg O. Iron, the Oxygen-Carrier of Respiration-Ferment. Science (New York, NY 1925; 61(1588): 575-82.
121. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (New York, NY 2009; 324(5930): 1029-33.
122. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2009; 29(3): 313-24.
123. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010; 35(8): 427-33.
124. Yun J, Rago C, Cheong I, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (New York, NY 2009; 325(5947): 1555-9.
125. Ramanathan A, Wang C, Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA 2005; 102(17): 5992-7.
126. Chiaradonna F, Gaglio D, Vanoni M, Alberghina L. Expression of transforming K-Ras oncogene affects mitochondrial function and morphology in mouse fibroblasts. Biochimica et Biophysica acta 2006; 1757(9-10): 1338-56.
127. Baracca A, Chiaradonna F, Sgarbi G, Solaini G, Alberghina L, Lenaz G. Mitochondrial Complex I decrease is responsible for bioenergetic dysfunction in K-ras transformed cells. Biochimica et biophysica acta 2010; 1797(2): 314-23.
128. Palorini R, De Rasmo D, Gaviraghi M, et al. Oncogenic K-ras expression is associated with derangement of the cAMP/PKA pathway and forskolin-reversible alterations of mitochondrial dynamics and respiration. Oncogene 2012 Mar 12.
129. Gaglio D, Metallo CM, Gameiro PA, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Systems Biol 2011; 7: 523.
130. Hu Y, Lu W, Chen G, et al. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res 2012; 22(2): 399-412.
131. Chun SY, Johnson C, Washburn JG, Cruz-Correa MR, Dang DT, Dang LH. Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1alpha and HIF-2alpha target genes. Mol Cancer 2010; 9: 293.
132. Fritz V, Fajas L. Metabolism and proliferation share common regulatory pathways in cancer cells. Oncogene 2010; 29(31): 4369-77.
133. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opinion Cell Biol 2001; 13(2): 167-71.
134. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opinion Genetics Development 2008; 18(1): 54-61.
135. Buzzai M, Bauer DE, Jones RG, et al. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 2005; 24(26): 4165-73.
136. Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004; 64(11): 3892-9.
137. Locasale JW, Grassian AR, Melman T, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nature Genetics 2011; 43(9): 869-74.
138. Jain M, Nilsson R, Sharma S, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science (New York, NY 2012; 336(6084): 1040-4.
139. Baum CE, Price DK, Figg WD. Sarcosine as a potential prostate cancer biomarker and therapeutic target. Cancer Biol Therapy 2010; 9(5): 341-2.
140. Jentzmik F, Stephan C, Lein M, et al. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol 2010; 185(2): 706-11.
141. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462(7274): 739-44.
142. Kalinina J, Carroll A, Wang L, et al. Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. J Mol Med (Berlin, Germany) 2012; 90(10): 1161-71.
143. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Experimental Med 2010; 207(2): 339-44.
144. Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012; 149(3): 656-70.
145. Garcia-Cao I, Song MS, Hobbs RM, et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 2012 Mar 30; 149(1): 49-62.
146. Steelman LS, Bertrand FE, McCubrey JA. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert opinion on therapeutic targets 2004; 8(6): 537-50.
147. Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 2008; 105(48): 18782-7.
148. Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458(7239): 762-5.
149. Yuneva MO, Fan TW, Allen TD, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell metabolism 2012; 15(2): 157-70.
150. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 2007; 178(1): 93-105.
151. Gaglio D, Soldati C, Vanoni M, Alberghina L, Chiaradonna F. Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PloS one 2009; 4(3): e4715.
152. Metallo CM, Gameiro PA, Bell EL, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2011; 481(7381): 380-4.
153. Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO reports 2011; 12(5): 463-9.
154. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer cell 2010; 18(6): 553-67.
155. Zhu J, Zuo J, Xu Q, Wang X, Wang Z, Zhou D. Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients. Medical Hypotheses 2011; 76(4): 602-3.
156. Seltzer MJ, Bennett BD, Joshi AD, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010; 70(22): 8981-7.
157. Le A, Lane AN, Hamaker M, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell metabolism 2012; 15(1): 110-21.
158. Shukla K, Ferraris DV, Thomas AG, et al. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem 2012; 55(23): 10551-63.
159. Balestrieri C, Vanoni M, Hautaniemi S, Alberghina L, Chiaradonna F. Integrative transcriptional analysis between human and mouse cancer cells provides a common set of transformation associated genes. Biotechnol Adv 2012; 30(1): 16-29.
160. Teusink B, Passarge J, Reijenga CA, et al. Can yeast glycolysis be understood in terms of in vitro kinetics of the constituent enzymes? Testing biochemistry. Eur J Biochem/FEBS 2000; 267(17): 5313-29.
161. Achcar F, Kerkhoven EJ, Bakker BM, Barrett MP, Breitling R. Dynamic modelling under uncertainty: the case of Trypanosoma brucei energy metabolism. PLoS computational Biol 2012; 8(1): e1002352.
162. Nazaret C, Mazat JP. An old paper revisited: "a mathematical model of carbohydrate energy metabolism. Interaction between glycolysis, the Krebs cycle and the H-transporting shuttles at varying ATPases load" by V.V. Dynnik, R. Heinrich and E.E. Sel'kov. J theoretical Biol 2008; 252(3): 520-9.
163. Konig M, Bulik S, Holzhutter HG. Quantifying the contribution of the liver to glucose homeostasis: a detailed kinetic model of human hepatic glucose metabolism. PLoS computational Biol 2012; 8(6): e1002577.
164. Bazil JN, Buzzard GT, Rundell AE. Modeling mitochondrial bioenergetics with integrated volume dynamics. PLoS Computational Biol 2010; 6(1): e1000632.
165. Nazaret C, Heiske M, Thurley K, Mazat JP. Mitochondrial energetic metabolism: a simplified model of TCA cycle with ATP production. J theoretical biology 2009; 258(3): 455-64.
166. Orth JD, Thiele I, Palsson BO. What is flux balance analysis? Nature Biotechnol 2010; 28(3): 245-8.
167. Hiller K, Metallo CM. Profiling metabolic networks to study cancer metabolism. Curr Opinion Biotechnol 2012 Nov 30.
168. Bordbar A, Palsson BO. Using the reconstructed genome-scale human metabolic network to study physiology and pathology. J internal Med 2012; 271(2): 131-41.
169. Frezza C, Zheng L, Tennant DA, et al. Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PloS one 2011; 6(9): e24411.
170. Frezza C, Zheng L, Folger O, et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 2011; 477(7363): 225-8.
171. Thiele I, Swainston N, Fleming RM, et al. A community-driven global reconstruction of human metabolism. Nature Biotechnol 2013 Mar 3.
172. Hatzivassiliou G, Zhao F, Bauer DE, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer cell 2005; 8(4): 311-21.
173. Cuperlovic-Culf M, Culf A, Touaibia M, Lefort N. Targeting the latest hallmark of cancer: another attempt at 'magic bullet' drugs targeting cancers' metabolic phenotype. Future Oncol (London, England) 2012; 8(10): 1315-30.
174. Krzeslak A, Wojcik-Krowiranda K, Forma E, et al. Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Pathol Oncol Res 2012; 18(3): 721-8.
175. Medina RA, Owen GI. Glucose transporters: expression, regulation and cancer. Biological Res 2002; 35(1): 9-26.
176. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev 2010; 10(4): 267-77.
177. Cao X, Fang L, Gibbs S, et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemotherap Pharmacol 2007; 59(4): 495-505.
178. Chan DA, Sutphin PD, Nguyen P, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Translational Med 2011; 3(94): 94ra70.
179. Hassanein M, Hoeksema MD, Shiota M, et al. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res 2012 Dec 4.
180. Wang JB, Erickson JW, Fuji R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer cell 2010; 18(3): 207-19.
181. Sonveaux P, Vegran F, Schroeder T, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Investigation 2008; 118(12): 3930-42.
182. Xie H, Valera VA, Merino MJ, et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Molecular cancer therapeutics 2009; 8(3): 626-35.
183. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Ann Rev Pathol 2006; 1: 119-50.
184. Fiaschi T, Marini A, Giannoni E, et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumorstroma interplay. Cancer Res 2012; 72(19): 5130-40.
185. Zheng XT, Yang HB, Li CM. Optical detection of single cell lactate release for cancer metabolic analysis. Analytical Chem 2010; 82(12): 5082-7.
186. Vegran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Res 2011; 71(7): 2550-60.
187. Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Frontiers in Pharmacol 2011; 2: 49.
188. Munoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. Cell Death Disease 2012; 3: e248.
189. Vander Heiden MG, Christofk HR, Schuman E, et al. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol 2010; 79(8): 1118-24.
190. Hitosugi T, Zhou L, Elf S, et al. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer cell 2012; 22(5): 585-600.
191. Clem B, Telang S, Clem A, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Therapeut 2008; 7(1): 110-20.
192. Ramos-Montoya A, Lee WN, Bassilian S, et al. Pentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancer. Int J cancer 2006; 119(12): 2733-41.
193. Vizan P, Alcarraz-Vizan G, Diaz-Moralli S, Solovjeva ON, Frederiks WM, Cascante M. Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29. Int J Cancer 2009; 124(12): 2789-96.
194. Zanuy M, Ramos-Montoya A, Villacanas O, et al. Cyclindependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle. Metabolomics 2012; 8(3): 454-64.
195. Rais B, Comin B, Puigjaner J, et al. Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. FEBS letters 1999; 456(1): 113-8.
196. Chen H, Yue JX, Yang SH, Ding H, Zhao RW, Zhang S. Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J Exp Clin Cancer Res 2009; 28: 43.
197. Schultz H, Kahler D, Branscheid D, Vollmer E, Zabel P, Goldmann T. TKTL1 is overexpressed in a large portion of non-small cell lung cancer specimens. Diagnostic Pathol 2008; 3: 35.
198. Foldi M, Stickeler E, Bau L, et al. Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer. Oncology reports 2007; 17(4): 841-5.
199. Obiol-Pardo C, Alcarraz-Vizan G, Cascante M, Rubio-Martinez J. Diphenyl urea derivatives as inhibitors of transketolase: a structurebased virtual screening. PloS one 2012; 7(3): e32276.
200. Michelakis ED, Sutendra G, Dromparis P, et al. Metabolic modulation of glioblastoma with dichloroacetate. Science translational Med 2010; 2(31): 31ra4.
201. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011; 10(9): 671-84.
202. Spruijt L, Naviaux RK, McGowan KA, et al. Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate. Muscle Nerve 2001; 24(7): 916-24.
203. Stacpoole PW, Henderson GN, Yan Z, James MO. Clinical pharmacology and toxicology of dichloroacetate. Environmental health perspectives 1998; 106 Suppl 4: 989-94.
204. Aicher TD, Anderson RC, Gao J, et al. Secondary amides of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase. J Med Chem 2000; 43(2): 236-49.
205. Bebernitz GR, Aicher TD, Stanton JL, et al. Anilides of (R)-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase. J medicinal chemistry 2000; 43(11): 2248-57.
206. Wallace DC. Mitochondria and cancer. Nature Rev 2012; 12(10): 685-98.
207. Hsia TC, Yang JS, Chen GW, et al. The roles of endoplasmic reticulum stress and Ca2+ on rhein-induced apoptosis in A-549 human lung cancer cells. Anticancer Res 2009; 29(1): 309-18.
208. Ip SW, Weng YS, Lin SY, et al. The role of Ca+2 on rhein-induced apoptosis in human cervical cancer Ca Ski cells. Anticancer Res 2007; 27(1A): 379-89.
209. Glover CJ, Rabow AA, Isgor YG, Shoemaker RH, Covell DG. Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia cell lines. Biochem Pharmacol 2007; 73(3): 331-40.
210. Grimberg H, Levin G, Shirvan A, et al. Monitoring of tumor response to chemotherapy in vivo by a novel small-molecule detector of apoptosis. Apoptosis 2009; 14(3): 257-67.
211. Gomez-Lazaro M, Galindo MF, Melero-Fernandez de Mera RM, et al. Reactive oxygen species and p38 mitogen-activated protein kinase activate Bax to induce mitochondrial cytochrome c release and apoptosis in response to malonate. Mol Pharmacol 2007; 71(3): 736-43.
212. Zhao Y, Neuzil J, Wu K. Vitamin E analogues as mitochondriatargeting compounds: from the bench to the bedside? Mol Nutrition Food Res 2009; 53(1): 129-39.
213. Pierotti MA, Berrino F, Gariboldi M, et al. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene 2012 Jun 4.
214. Chiarugi A, Dolle C, Felici R, Ziegler M. The NAD metabolome-a key determinant of cancer cell biology. Nat Rev 2012; 12(11): 741-52.
215. Swinnen JV, Van Veldhoven PP, Timmermans L, et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into de tergent-resistant membrane microdomains. Biochem Biophysical Res Communicat 2003; 302(4): 898-903.
216. Kridel SJ, Lowther WT, Pemble CWt. Fatty acid synthase inhibitors: new directions for oncology. Expert Opinion Investigat Drugs 2007; 16(11): 1817-29.
217. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature reviews 2007; 7(10): 763-77.
218. Menendez JA, Vellon L, Lupu R. Antitumoral actions of the antiobesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol 2005; 16(8): 1253-67.
219. Migita T, Narita T, Nomura K, et al. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res 2008; 68(20): 8547-54.
220. Pearce NJ, Yates JW, Berkhout TA, et al. The role of ATP citratelyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citratelyase inhibitor SB-201076. The Biochem J 1998; 334 (Pt 1): 113-9.
221. Wang C, Rajput S, Watabe K, Liao DF, Cao D. Acetyl-CoA carboxylase-a as a novel target for cancer therapy. Frontiers in bioscience (Scholar edition) 2010; 2: 515-26.
222. Guseva NV, Rokhlin OW, Glover RA, Cohen MB. TOFA (5-tetradecyl-oxy-2-furoic acid) reduces fatty acid synthesis, inhibits expression of AR, neuropilin-1 and Mcl-1 and kills prostate cancer cells independent of p53 status. Cancer Biol Therap 2011; 12(1): 80-5.
223. Beckers A, Organe S, Timmermans L, et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res 2007; 67(17): 8180-7.
224. Nieman KM, Kenny HA, Penicka CV, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nature Med 2011; 17(11): 1498-503.
225. Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science (New York, NY 2002; 297(5578): 63-4.
226. Sharma SV, Gajowniczek P, Way IP, et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer cell 2006; 10(5): 425-35.
227. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Development 2007; 21(24): 3214-31.
228. Weinstein IB. Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 2000; 21(5): 857-64.
229. Weinstein IB, Begemann M, Zhou P, et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res 1997; 3(12 Pt 2): 2696-702.
230. Hood L, Perlmutter RM. The impact of systems approaches on biological problems in drug discovery. Nature Biotechnol 2004; 22(10): 1215-7.
231. Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. Nature Clin Practice 2006; 3(8): 448-57.
232. Sebastian C, Zwaans BM, Silberman DM, et al. The Histone Deacetylase SIRT6 Is a Tumor Suppressor that Controls Cancer Metabolism. Cell 2012; 151(6): 1185-99.
233. Robinson GL, Dinsdale D, Macfarlane M, Cain K. Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAIL. Oncogene 2012; 31(48): 4996-5006.
234. Ros S, Santos CR, Moco S, et al. Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer Discov 2012; 2(4): 328-43.
235. Yamaguchi R, Perkins G. Challenges in targeting cancer metabolism for cancer therapy. EMBO reports 2012; 13(12): 1034-5.
236. Yamaguchi R, Perkins G. Finding a Panacea among combination cancer therapies. Cancer Res 2012; 72(1): 18-23.
237. Kitano H. Cancer as a robust system: implications for anticancer therapy. Nat Rev 2004; 4(3): 227-35.
238. Kitano H. Towards a theory of biological robustness. Mol Systems Biol 2007; 3: 137.
239. Kitano H. The theory of biological robustness and its implication in cancer. Ernst Schering Res Foundation workshop 2007(61): 69-88.
240. Moreno-Sanchez R, Saavedra E, Rodriguez-Enriquez S, Gallardo-Perez JC, Quezada H, Westerhoff HV. Metabolic control analysis indicates a change of strategy in the treatment of cancer. Mitochondrion 2010; 10(6): 626-39.